New AI-powered segmentation tool and imaging-system integration to be showcased in Copenhagen
Booth D39, September 5–9, Copenhagen, Denmark
MONTPELLIER, France & MIAMI–(BUSINESS WIRE)–Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will unveil new features for its Epione® robotic platform at the 2026 annual congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Copenhagen, Denmark, September 5–9, on Booth D39. The updated platform will feature new AI capabilities and compatibility with one of the latest-generation angiography systems from GE HealthCare enabling greater mobility.
Epione is an AI- and robotic-assisted percutaneous ablation platform that integrates every step of the procedure — planning, targeting, delivery, and confirmation. Epione is used to treat abdominal, chest, and musculoskeletal tumors and lesions1, and is also available for bone consolidation procedures2.
At CIRSE, Precision IO will introduce two new capabilities:
- Smart Seg AI, a software tool powered by deep-learning algorithms trained on thousands of CT scan images optimizing the segmentation of tumors in the liver
- The compatibility with the Allia™ Moveo3 INTERACT Touch panel, developed in collaboration with GE HealthCare, an industry leader, to offer physicians a seamless experience. Combining high-quality 3D imaging, treatment-planning capabilities, and robotic needle guidance, the integrated solution supports accurate target visualization and precise needle placement for complex percutaneous procedures.
“Our collaboration with GE HealthCare reflects a shared commitment to innovation and to advancing the future of image-guided interventions. We are proud that the flexibility of the Epione® platform and our team’s expertise have enabled a seamless integration with the Allia™ Moveo INTERACT Touch panel, creating a more streamlined workflow that allows physicians to stay focused on what matters most: the patient,” said Kurt Azarbarzin, CEO of Precision IO Group, parent company of Quantum Surgical.
Precision IO will host hands-on sessions and demos at the GE HealthCare Booth D40 on:
- Sunday, September 6, 11:45–12:30
- Monday, September 7, 11:45–12:30
In addition, Yann Le Meur, PhD, Director of Innovation & Technology at Quantum Surgical (Precision IO Group), will speak as part of the SPHAIRE Lecture series:
- Tuesday, September 8, 10:00–11:00 — SPHAIRE News on Stage
As part of session SPH 428 — Robotics and Human–Machine Interaction, Le Meur will present “Robotics in Interventional Oncology: The Value of Collaborative Controls.” The talk will give the interventional radiology community a perspective on how robotics and human–machine collaboration are shaping the future of interventional oncology.
About Precision IO Group
Precision IO Group is a private interventional oncology company advancing the technologies physicians use to perform minimally invasive treatment of solid tumors. The company’s two operating subsidiaries — NeuWave Medical and Quantum Surgical — develop and commercialize microwave ablation systems and the Epione® robotic ablation platform, respectively.
Precision IO Group was formed in 2026 following the acquisition of NeuWave Medical from Johnson & Johnson MedTech, is backed by Ally Bridge Group, and employs more than 275 people worldwide. The company’s mission is to make precision cancer care universally available, empowering physicians to treat more challenging lesions with consistent, evidence-backed solutions.
By integrating robotics, artificial intelligence, and remote-enabled interventions, Precision IO Group aims to advance the standard of care in tumor ablation.
More information: www.precisionIO.com
| ______________________________ |
|
1 The Epione device is CE marked for abdominal, chest, and musculoskeletal structures indications with CT and CBCT image guidance, and FDA cleared for the abdominal ablation indication with CT. |
|
2 In the United States, use of the Epione platform for musculoskeletal (MSK) applications, including bone, is investigational and has not been cleared by the FDA. MSK use is being studied in the pelvis and spine as part of an ongoing Investigational Device Exemption (IDE) clinical study (ClinicalTrials.gov: NCT07325578). |
|
3 Allia™ is a trademark of GE HealthCare. Commercial availability of GE HealthCare medical systems is subject to meeting local requirements in a given country or region. Contact a GE HealthCare representative for more information. Intended for healthcare professionals only. ©2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. |
Contacts
Press Contact Precision IO Group
Stéphanie Moy
[email protected]
Tel. : +33 (0)6 32 55 85 48
